Drug Profile
Cobicistat/elvitegravir/emtricitabine/tenofovir disoproxil fumarate - Gilead Sciences/Japan Tobacco
Alternative Names: Elvitegravir/Truvada/GS 9350; EVG/COBI/FTC/TDF; EVG/FTC/TDF/cobicistat FDC Quad tablet; Quad; StribildLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Gilead Sciences; Japan Tobacco
- Class Antiretrovirals; Deoxyribonucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides; Quinolones; Small molecules
- Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 23 Feb 2021 No development reported - Phase-II/III for HIV-1 infections (In adolescents, In children, Treatment-naive) in South Africa, Thailand, USA (PO) (Gilead Sciences pipeline, February 2021)
- 05 Dec 2018 Gilead offered Japan Tobacco to terminate the exclusive licenses for HIV drugs
- 06 Sep 2018 Gilead Sciences completes the WAVES phase IIIb trial in HIV infections (Treatment-naive) in USA, Belgium, Dominican Republic, France, Italy, Mexico, Portugal, Puerto Rico, Thailand, Russia, Uganda and United Kingdom (NCT01705574)